Clinical Trials | November 10, 2025
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
Poviztra is a second brand of Wegovy
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Subscribe To Our Newsletter & Stay Updated
